GLUE$10.631.21%-0.13
Pre-market: 10.75+0.12 +1.13%
Monte Rosa Therapeutics Inc (GLUE)
Date: 2026-11-02 16:00O: 10.79H: 11.02L: 10.43C: 10.63Vol: 1.767M
Monte Rosa Therapeutics Inc stock is traded at $10.63, with a volume of 1,767,022. It is down -1.21% in the last 24 hours and up +1.24% over the past month. Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Previous Close:
$10.76
Open:
$10.79
24h Volume:
1,767,022
Relative Volume:
1.28
Market Cap:
$906.88M
Revenue:
$42.95M
Net Income/Loss:
-$130.01M
P/E Ratio:
-
EPS:
-$1.63
Net Cash Flow:
-$19.66M
1W Performance:
-0.28%
1M Performance:
+1.24%
6M Performance:
-43.46%
1Y Performance:
-11.93%
1-Day Range:
$0.00$0.00
1-Week Range:
$10.40$11.20
52-Week Range:
$9.68$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-949-2643Address
321 HARRISON AVENUE, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
- Bowen MatthewOct 05 '26Principal Accounting Officer
- Transaction
- Sale
- Cost
- $10.56
- #Shares
- 13
- Value ($)
- 137
- #Shares Total
- 25,891
- MARKUS WARMUTHJul 16 '26Officer
- Transaction
- Proposed Sale
- Cost
- $23.18
- #Shares
- 9,500
- Value ($)
- 220,219
- #Shares Total
- 0
- Warmuth MarkusJul 16 '26President & CEO
- Transaction
- Sale
- Cost
- $23.18
- #Shares
- 9,500
- Value ($)
- 220,219
- #Shares Total
- 585,038
- Champoux JenniferJul 15 '26Chief Operating Officer
- Transaction
- Option Exercise
- Cost
- $3.98
- #Shares
- 4,351
- Value ($)
- 17,317
- #Shares Total
- 66,722
- Champoux JenniferJul 15 '26Officer
- Transaction
- Proposed Sale
- Cost
- $23.38
- #Shares
- 4,351
- Value ($)
- 101,730
- #Shares Total
- 0
- Champoux JenniferJul 15 '26Chief Operating Officer
- Transaction
- Sale
- Cost
- $23.38
- #Shares
- 4,351
- Value ($)
- 101,730
- #Shares Total
- 62,371
- Townson SharonJul 06 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $23.31
- #Shares
- 6,000
- Value ($)
- 139,849
- #Shares Total
- 67,845
- Townson SharonJul 06 '26Chief Scientific Officer
- Transaction
- Option Exercise
- Cost
- $6.14
- #Shares
- 6,000
- Value ($)
- 36,840
- #Shares Total
- 73,845
- FILIP JANKUJun 30 '26Officer
- Transaction
- Proposed Sale
- Cost
- $23.90
- #Shares
- 5,407
- Value ($)
- 129,227
- #Shares Total
- 0
- Janku FilipJun 30 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $13.41
- #Shares
- 5,407
- Value ($)
- 72,508
- #Shares Total
- 66,019
